CAMBRIDGE NUCLEOMICS LTD

13135667
Active Cambridge

Research and experimental development on biotechnology

2 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
C

CAMBRIDGE NUCLEOMICS LTD

13135667

Research and experimental development on biotechnology

Founded 15 Jan 2021 Active Cambridge, England 2 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 23 Mar 2026 Next due 31 Mar 2026 3 months overdue
Confirmation Submitted 28 Jan 2026 Next due 28 Jan 2027 7 months remaining
Net assets £399K £506K 2025 year on year
Total assets £549K £513K 2025 year on year
Total Liabilities £150K £7K 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Meditrina Building Babraham Research Campus Cambridge CB22 3AT England

Website

www.example.com

Full company profile for CAMBRIDGE NUCLEOMICS LTD (13135667), an active life sciences and medical technology company based in Cambridge, England. Incorporated 15 Jan 2021. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jul → 30 Jun 2025
Type total-exemption-full
Next accounts 30 Jun 2025
Due by 31 Mar 2026 3 months overdue

Net Assets, Total Assets & Total Liabilities (2022–2025)

Cash in Bank

£527.58k

Increased by £517.19k (+4979%)

Net Assets

£399.09k

Increased by £506.39k (+472%)

Total Liabilities

£149.79k

Increased by £6.94k (+5%)

Turnover

N/A

Employees

2

Debt Ratio

27%

Decreased by 375 (-93%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
30 Jun Year End
2024
30 Jun Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

14 Allotments 8,208,387 Shares £11.93m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
6 Mar 20251,326,790£311k£0.234
6 Mar 2025640,000£0.64£0
3 Mar 20251,001,597£235k£0.234
28 Oct 20221,454,000£2.12m£1.46
28 Oct 202241,000£2k£0.05

Officers

Officers

2 active 1 resigned
Status
Cooke, Anthony, DrDirectorBritishEngland7026 Jan 2026Active
Ulrich Felix KeyserDirectorGermanEngland5117 May 2021Active

Shareholders

Shareholders (28)

Hendrik Runge
36.5%
3,000,000
Ulrich Keyser
18.3%
1,500,000

Persons with Significant Control

Persons with Significant Control (2)

2 Active 1 Ceased

Ulrich Felix Keyser

German

Active
Notified 15 Jan 2021
Residence England
DOB March 1975
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Mr Hendrik Friedrich Peter Runge

German

Active
Notified 28 Oct 2022
Residence England
DOB February 1991
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent

Max Zhu

Ceased 1 Aug 2022

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
23 Mar 2026AccountsAnnual accounts made up to 30 Jun 2025
28 Jan 2026Persons With Significant ControlChange to Mr Hendrik Friedrich Peter Runge as a person with significant control on 3 Mar 2025
28 Jan 2026Confirmation StatementConfirmation statement made on 14 Jan 2026 with updates
28 Jan 2026OfficersAppointment of Dr Anthony Cooke as director on 26 Jan 2026
28 Jan 2026Persons With Significant ControlCessation of Ulrich Felix Keyser as a person with significant control on 3 Mar 2025
23 Mar 2026 Accounts

Annual accounts made up to 30 Jun 2025

28 Jan 2026 Persons With Significant Control

Change to Mr Hendrik Friedrich Peter Runge as a person with significant control on 3 Mar 2025

28 Jan 2026 Confirmation Statement

Confirmation statement made on 14 Jan 2026 with updates

28 Jan 2026 Officers

Appointment of Dr Anthony Cooke as director on 26 Jan 2026

28 Jan 2026 Persons With Significant Control

Cessation of Ulrich Felix Keyser as a person with significant control on 3 Mar 2025

Recent Activity

Latest Activity

Annual accounts made up to 30 Jun 2025

2 months ago on 23 Mar 2026

Change to Mr Hendrik Friedrich Peter Runge as a person with significant control on 3 Mar 2025

4 months ago on 28 Jan 2026

Confirmation statement made on 14 Jan 2026 with updates

4 months ago on 28 Jan 2026

Appointment of Dr Anthony Cooke as director on 26 Jan 2026

4 months ago on 28 Jan 2026

Cessation of Ulrich Felix Keyser as a person with significant control on 3 Mar 2025

4 months ago on 28 Jan 2026